Revenue segments as reported by the company.

Net revenue, before excise taxes

Excise taxes

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

Research and development

General and administrative

Restructuring costs

Share-based payments

Depreciation and amortization

Impairment loss on goodwill and indefinite-lived intangible assets

Impairment loss on long-lived assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cronos Group

Cronos Group, Inc. engages in the production and distribution of cannabis. Its brands include PEACE NATURALS, COVE, Spinach, Lord Jones, and PEACE+. The company was founded by Lorne Michael Gertner and Paul Rosen on August 21, 2012 and is headquartered in Toronto, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cronos Group, Inc. engages in the production and distribution of cannabis. I It operates through the Canada and Israel segments. The company was founded on August 21, 2012 and is headquartered in Toronto, Canada.

CRON's ability to push its sales higher is limited, meaning that any rally by CRON stock probably won't last very long.
The post Should Long-Term Investors Buy Cronos Group Stock in October?

Should Long-Term Investors Buy Cronos Group Stock in October?

The deep sell-off in cannabis stocks is not yet over. Cronos stock is getting caught up, too, but long-term investors should hold tight.

Cronos Stock Is a Buy if You Can Handle the Wild Ride Ahead

This cannabis stock is poised to see a significant fall sometime in the future.

Why Cronos Group Is Overvalued Right Now

TORONTO, Sept.  30, 2019  (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) today announced that, in connection with its investment in the Company, Altria Group, Inc. (“Altria”) has appointed Jody Begley to the Cronos Group Board of Directors. Mr. Begley is currently Senior Vice President, Tobacco Products for Altria Group in which he oversees more than $24 billion in net revenues. Altria’s appointment replaces one of its previous director designees, K.C. Crosthwaite, who has resigned from the Cronos Group Board to devote more time to his new position as CEO of JUUL Labs.

Cronos Group Announces Appointment of Jody Begley to Board of Directors

While cannabis investments like Cronos Group stock have done well earlier in the game, this sector has lost significant credibility. As such, you don’t want to spend too much money on CRON, which is both technically and fundamentally weak.

How to Trade Cronos Group Stock as More Support Fails

Cronos Group was already struggling to turn a profit and gain market share. Now the deterioration of a growth prospect could completely up-end CRON stock.

Going Big on Vaping Is a Serious Headwind for Cronos Stock

Aurora Cannabis

Don't sleep on the potential of medical marijuana.

Forget Recreational Marijuana: 5 Reasons Medical Cannabis Is the Smarter Play

Canopy Growth

In an industry where issuing stock has become commonplace, cash has lost its luster.

In the Marijuana Industry, Cash Isn't King

Cronos may have an advantage in cannabinoid production, due to a strategic partnership. That could help CRON stock.

Cronos Group Stock May Get Boost From Cannabinoid Production

GW Pharmaceuticals

Tilray Brands

Zynerba Pharmaceuticals

Cannabis (or marijuana) based medical products have the potential to become the next booming industry.

Epidolex Progresses: Will the Marijuana Drug Market Boom?

Cannabis Stocks Plunge Following Analyst Warning

Amazon

BlackBerry

Shopify

Tesla

Amazon, Tesla, Cronos Group, Shopify and BlackBerry were our top stock trades to watch on Wednesday. See the charts, now.

5 Top Stock Trades for Wednesday: AMZN, CRON, TSLA, SHOP & BB

TORONTO, Sept.  24, 2019  (GLOBE NEWSWIRE) -- Cronos Group Inc. (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and Chief Executive Officer, will speak at the CIBC 18th Annual Eastern Institutional Investors Conference on Wednesday September 25, 2019 at 3:25 p.m. ET in Montreal, QC.

Cronos Group Inc. CEO, Mike Gorenstein, to Present at the CIBC 18th Annual Eastern Institutional Investors Conference

Cannabis store sales hit an all-time high in July, but are still pacing below lofty expectations.

Canada Has Sold This Much Marijuana Since Its Legalization Day

Here's a peek into the cannabis stock's future.

Where Will Cronos Group Be in 5 Years?

The vaping crackdown shook some investors out of CRON stock, but there could be a turnaround in the offing.
The post Worried About the Vaping Controversy?

Worried About the Vaping Controversy? Relax and Buy CRON Stock

MedMen Enterprises Inc.

Brand-name marijuana stocks don't always make for the best investments.

3 Pot Stocks I Wouldn't Buy With Free Money

Greenlane Holdings

Neptune Wellness Solutions Inc.

The CDC has confirmed 530 cases of mysterious lung illnesses tied to vaping, along with seven deaths. Here's how it'll impact the fast-growing pot industry.

Vape Health Concerns: The Cannabis Winners and Losers

This is not the first time the two companies have worked together.

Cronos Group and MediPharm Labs Sign Vaporizer Deal

To be fair, Cronos posted an increase in sales during the second quarter, but its negative cash flow position also rose and some analysts continue questioning the company's position in its home market of Canada.

Cronos Group Stock is Still Expensive Despite Allure of International Plans

Cannabis company Cronos Group Inc (NASDAQ: CRON) plans on launching vaping devices in Canada with a focus on safety, quality and proper ingredients, company founder and CEO Mike Gorenstein told CNBC's Jim Cramer.

Cronos CEO Talks Vaping With Cramer

CRON stock looks unlikely to make any upward movement in the near term, making it a poor choice in the marijuana space right now.
The post Now Is Not the Time to Buy Cronos Stock appeared first on InvestorPlace.

Now Is Not the Time to Buy Cronos Stock

Canadian headwinds are holding back Cronos Group stock as the next deregulation phase looms. Still CRON stock is doing better than peers.

Cronos Group Stock Continues to Lag as Canada Headwinds Hold Back Sector

Investor sentiment toward the cannabis industry can shift quickly.

News for Cronos Group Stock (CRON)